Hormone replacement therapy shifts where your body stores fat, primarily by changing the balance between visceral fat (the deep abdominal kind wrapped around organs) and subcutaneous fat (the kind stored under the skin in places like hips, thighs, and buttocks). The direction and magnitude of that shift depend on which hormones are involved, whether estrogen is being added or removed from the equation, and the context of treatment. In postmenopausal women, estrogen-based HRT tends to counteract the midlife drift toward belly fat. In transgender women receiving feminizing hormone therapy, the same hormonal logic drives fat toward a more typically female pattern. The mechanisms behind these changes run deeper than most people realize, reaching down to how individual fat cells are born, how large they grow, and how readily they release stored energy.
Why Hormones Control Where Fat Lives
Men and women carry fat in different places, and this is not a subtle difference. Women store more subcutaneous fat, particularly in the hips, thighs, and buttocks, while men accumulate more visceral fat in the abdominal cavity.1PubMed. Sexual dimorphism in body fat distribution and risk for cardiovascular diseases Even when total body fat is similar, the distribution pattern diverges sharply between the sexes, with women showing a lower ratio of abdominal-to-hip fat.2The Journal of Nutrition, Health and Aging. The body fat-cognition relationship in healthy older individuals: Does gynoid vs android distribution matter? This pattern is not fixed by anatomy or genetics alone. It is actively maintained by circulating sex hormones, which is why fat distribution changes whenever the hormonal environment shifts, whether from menopause, medical treatment, or gender-affirming therapy.
The protective value of the female fat pattern is worth understanding. Premenopausal women have much lower rates of obesity-related metabolic disorders than men of the same age, and the subcutaneous distribution of their fat is a major reason.1PubMed. Sexual dimorphism in body fat distribution and risk for cardiovascular diseases Visceral fat is metabolically active in ways that subcutaneous fat is not, pumping out inflammatory signals and interfering with insulin function. When menopause removes estrogen from the picture, women begin accumulating visceral fat and losing that metabolic advantage.
How Estrogen and Androgens Act on Fat Cells
The mechanisms are not a single switch but a set of overlapping effects that operate at different levels. Estrogen influences fat cells in at least two major ways. First, it regulates adipocyte size. In animal models, estrogen treatment reduced the overall mass of fat tissue and shrank individual fat cells, while simultaneously down-regulating the genes responsible for making new fat (lipogenesis).3Journal of Biological Chemistry. Estrogen Regulation of Adiposity and Fuel Partitioning: Evidence of Genomic and Non-genomic Regulation of Lipogenic and Oxidative Pathways Second, estrogen made those fat cells more responsive to catecholamines, the stress hormones that trigger fat breakdown. Fat cells in estrogen-treated animals contained over three times more perilipin protein, a molecule that regulates how fat droplets are accessed for energy, which translated to a stronger lipolytic response when the body needed to mobilize stored fuel.3Journal of Biological Chemistry. Estrogen Regulation of Adiposity and Fuel Partitioning: Evidence of Genomic and Non-genomic Regulation of Lipogenic and Oxidative Pathways
Androgens act through a different and in some ways opposing channel. Testosterone and its potent derivative DHT inhibit the earliest stages of fat cell development. When human fat stem cells were exposed to these androgens during the commitment phase, the cells failed to properly acquire lipid and showed suppressed expression of the master fat-cell regulators. Androgens essentially blocked the molecular signal (BMP4) that tells stem cells to become fat cells in the first place.4PubMed Central. Androgens inhibit adipogenesis during human adipose stem cell commitment to preadipocyte formation The result is fewer new fat cells being created in subcutaneous depots, which limits the capacity for fat storage in those areas.
What makes the redistribution story more interesting is that testosterone’s metabolites affect different fat depots differently. In castrated mice given hormone replacement, testosterone itself blocked fat growth in both visceral and subcutaneous compartments. But when researchers tracked the individual metabolites, estradiol (which testosterone converts into) selectively blocked visceral fat growth, while DHT selectively blocked subcutaneous fat growth. These effects were driven by depot-specific changes in fat cell size, not just cell number.5PubMed Central. Testosterone metabolites differentially regulate obesogenesis and fat distribution This explains part of why the balance between estrogen and androgens determines where fat ends up: the two hormone classes are pulling in different regional directions.
Adding another layer, sex hormone receptors are not evenly distributed across the body’s fat depots. In men with coronary artery disease, androgen receptor expression in leg fat tissue was substantially higher than in chest wall or heart-surrounding fat, and aromatase, the enzyme that converts testosterone to estrogen, was also more active in peripheral fat.6PubMed. Expression of sex steroid receptors and aromatase in adipose tissue in different body regions in men with coronary artery disease with and without ischemic systolic heart failure This uneven receptor landscape means the same circulating hormone can have very different effects depending on where the fat tissue sits, which helps explain why hormonal changes do not simply make you gain or lose fat everywhere equally.
Estrogen and Brown Fat Thermogenesis
Beyond controlling where white fat accumulates, estrogen also influences brown adipose tissue, the calorie-burning fat that generates heat. Estrogen modulates the expression of adrenergic receptors in brown fat in a way that amplifies and prolongs the metabolic response to sympathetic nervous system activation. In females with normal estrogen levels, brown fat responds more vigorously and for longer periods when the sympathetic nervous system fires. Testosterone has the opposite effect, down-regulating the receptors that promote thermogenesis and up-regulating the ones that dampen it, making brown fat in males more resistant to activation.7PubMed Central. The capacity for oestrogen to influence obesity through brown adipose tissue thermogenesis in animal models: A systematic review and meta‐analysis This means estrogen does not just redirect fat storage; it also influences the rate at which your body burns energy through heat generation, adding to its overall effect on body composition.
What Happens During Menopause and How HRT Responds
When estrogen levels drop at menopause, the protective fat distribution pattern erodes. The hallmark change is a shift toward abdominal fat accumulation. While the total weight gain that many women experience in midlife is driven by aging and lifestyle factors rather than menopause itself, the redistribution of fat toward the trunk is specifically tied to the hormonal transition.8PubMed. Understanding weight gain at menopause Estrogen deficiency is a key factor in the emergence of cardiovascular risk during this period, characterized by unfavorable changes in blood lipids and the accumulation of visceral abdominal fat.9PubMed Central. Estrogen Deficiency and the Origin of Obesity during Menopause
Estrogen therapy can blunt this shift. In one prospective study of early postmenopausal women, a significant change from a hip-dominant to a belly-dominant fat pattern was observed only in the group not receiving hormones (their waist-to-hip ratio rose from about 0.80 to 0.85 over the study period), while women on combined estrogen-progestin therapy showed essentially no change.10PubMed. Effects of hormone replacement therapy on weight, body composition, fat distribution, and food intake in early postmenopausal women: a prospective study The treatment did not prevent weight gain itself, but it prevented the redistribution of that weight toward the abdomen.
Longer-term data from a large cohort study (OsteoLaus) showed that women who were current users of menopausal hormone therapy had lower visceral fat and lower android fat mass than women who had never used it, with the ten-year gain in visceral and android fat being prevented in current users.11The Journal of Clinical Endocrinology & Metabolism. Menopausal Hormone Therapy Is Associated With Reduced Total and Visceral Adiposity: The OsteoLaus Cohort This suggests the benefit is not a one-time correction but an ongoing maintenance of the more favorable distribution pattern for as long as treatment continues.
Your Starting Fat Pattern Matters
Not everyone responds to menopausal HRT the same way, and one of the strongest predictors of how much your fat distribution changes is where you started. A study of Japanese postmenopausal women found that those who already had a belly-dominant (android) fat pattern saw real reductions in visceral fat with HRT, and the proportion maintaining that android pattern decreased. But women who started with a hip-dominant (gynoid) pattern saw no significant change in their fat distribution on treatment.12PubMed. Effects of hormone replacement therapy on weight, abdominal fat distribution, and lipid levels in Japanese postmenopausal women In practical terms, if you have already shifted toward belly fat by the time you start HRT, you are more likely to see a measurable redistribution benefit. If you have maintained a more peripheral fat pattern, there may be less redistribution to detect, though you may still benefit from the prevention of future central fat gain.
Fat Redistribution in Gender-Affirming Hormone Therapy
The fat redistribution effects of hormones are perhaps most visible in transgender individuals, where the hormonal environment is being substantially remodeled. In trans women receiving feminizing therapy (estrogen plus anti-androgens), total body fat increases, and the pattern of where that fat goes shifts toward a more typically female distribution. A European study found that trans women gained about 4 kg of total body fat, but the amount of visceral fat did not change, resulting in roughly a 17% decrease in the ratio of visceral-to-total-body fat.13PubMed Central. Change in Visceral Fat and Total Body Fat and the Effect on Cardiometabolic Risk Factors During Transgender Hormone Therapy The new fat went to subcutaneous depots rather than the abdominal cavity, shifting the distribution pattern in a more gynoid direction.
MRI-based measurements confirmed this pattern. After six months of feminizing hormone therapy, the ratio of visceral-to-subcutaneous fat dropped significantly, meaning that relatively more fat was being stored under the skin and proportionally less around the organs.14PubMed Central. The effects of gender-affirming hormone therapy on myocardial, hepatic, pancreatic lipid content, body fat distribution and other cardiometabolic risk factors: A magnetic resonance-based study in transgender individuals An Indian study of 32 trans women reported a roughly 9% increase in total subcutaneous fat alongside an 11% increase in visceral fat, a somewhat different balance than the European findings.15PubMed Central. Body composition following gender affirming hormone therapy in transgender individuals This discrepancy is a good reminder that population, dosing protocol, duration of treatment, and measurement technique all influence the numbers researchers report.
For trans men receiving testosterone, the pattern reverses. Total body fat decreased by about 2.8 kg, while visceral fat again remained roughly stable, causing the visceral-to-total-fat ratio to increase by about 14%.13PubMed Central. Change in Visceral Fat and Total Body Fat and the Effect on Cardiometabolic Risk Factors During Transgender Hormone Therapy The loss came predominantly from subcutaneous stores, yielding a more android distribution. Both directions of change are consistent with the cellular mechanisms described earlier: estrogen favoring subcutaneous fat and limiting visceral growth, androgens inhibiting subcutaneous fat cell formation.
Metabolic Effects Beyond Appearance
Fat redistribution is not just cosmetic. Because visceral fat is the metabolically dangerous variety, the question of whether HRT changes its quantity has real implications for cardiovascular and metabolic risk. The picture here is not entirely clean-cut. In obese postmenopausal women, HRT users showed lower visceral fat and a more favorable body composition than nonusers, yet insulin sensitivity did not differ between the two groups.16PubMed. Relationship between hormone replacement therapy use with body fat distribution and insulin sensitivity in obese postmenopausal women A separate analysis found that the relationship between visceral fat and insulin sensitivity was actually modified by HRT status: among women with higher visceral fat levels, HRT users had better insulin sensitivity than nonusers, but among women with lower visceral fat, HRT users had slightly worse insulin sensitivity.17PubMed. Fat distribution and insulin sensitivity in postmenopausal women: influence of hormone replacement
At least one randomized trial found that HRT did not significantly affect body composition, fat distribution, or key inflammatory markers like IL-6, leptin, or adiponectin.18PubMed Central. Insulin resistance with hormone replacement therapy: associations with markers of inflammation and adiposity The discrepancy with observational studies likely reflects differences in study duration, dosing, the specific hormones used, and whether the participants were early or late in their menopausal transition. This is one of those areas where the evidence genuinely points in multiple directions, and blanket claims about metabolic benefits should be viewed with some skepticism.
Oral Versus Transdermal Delivery
How you take estrogen may matter as much as whether you take it, at least for certain metabolic outcomes. Oral estrogen passes through the liver before reaching the rest of the body, a process called first-pass metabolism. This means the liver sees much higher concentrations of the hormone than any other tissue, which triggers pronounced effects on liver protein production, blood-clotting factors, and inflammatory markers. Transdermal estrogen (patches, gels) bypasses this liver pass, reaching the circulation directly and producing more stable blood levels without the supraphysiologic liver exposure.19PubMed. Are all estrogens created equal? A review of oral vs. transdermal therapy
For fat metabolism specifically, the liver’s response to oral estrogen can raise triglyceride levels, while transdermal delivery tends to leave triglycerides unchanged. This has downstream consequences. In a study comparing the two routes over twelve months, non-alcoholic fatty liver disease was found in about 17% of the transdermal group versus roughly 29% of the oral group. Progression of fatty liver (new cases or worsening of pre-existing disease) was also markedly lower with transdermal delivery, at about 3% compared to 11% for oral.20Scientific Reports. Different effects of menopausal hormone therapy on non-alcoholic fatty liver disease based on the route of estrogen administration The incidence of metabolic syndrome and weight gain also appeared slightly lower with transdermal delivery.19PubMed. Are all estrogens created equal? A review of oral vs. transdermal therapy
These differences do not mean oral estrogen is the wrong choice for everyone. The two routes have different risk-benefit profiles across clotting risk, bone density, lipid effects, and convenience, and the best choice depends on individual medical history. But for people specifically concerned about fat metabolism and liver health, the transdermal route has a more favorable evidence profile.
Environmental Chemicals and Fat Storage
Hormones are not the only molecules that influence where and how much fat your body stores. A class of environmental chemicals known as endocrine disruptors can mimic or interfere with hormone signaling, and some of them directly promote fat cell formation. These compounds, found in pesticides, plastics, flame retardants, detergents, and personal care products, have been termed “obesogens” for their demonstrated ability to drive fat accumulation in both animal models and human epidemiological data.21PubMed Central. Endocrine Disruptors and Obesity Because these chemicals are fat-soluble, they tend to accumulate in fat tissue, which creates a feedback loop: more fat means greater capacity to retain the very chemicals that promote further fat deposition.
Exposure during fetal development and early life appears to be a particularly sensitive window. This matters for the HRT conversation because anyone undergoing hormone therapy is deliberately altering their endocrine environment, and background exposure to obesogens could interact with that shift in ways that are not yet well characterized. At minimum, the existence of these compounds means that hormone therapy operates against a backdrop of other endocrine influences that vary from person to person and environment to environment, adding one more source of individual variability in outcomes.
How Fat Redistribution Is Measured and Why It Matters
If you read studies on HRT and fat redistribution, the numbers you see are only as reliable as the measurement tools behind them, and those tools have real limitations. The most common clinical method is dual-energy X-ray absorptiometry (DXA), which is relatively quick and inexpensive. DXA correlates well with MRI for measuring visceral and subcutaneous fat, but it is not interchangeable with MRI for all purposes.22PubMed Central. MRI Based Validation of Abdominal Adipose Tissue Measurements From DXA in Postmenopausal Women In postmenopausal women, DXA’s regional fat percentage has been identified as a better predictor of visceral fat volume than waist circumference or BMI, making it a useful clinical screening tool in that population.23PubMed. Usefulness of lumbar AP spine DXA for measuring the percentage of perilumbar regional fat and predicting visceral fat in obese postmenopausal women
The bigger problem is lean mass. A recent comparison of DXA and MRI found that DXA substantially overestimates lean mass, particularly in the android region. In men, DXA measured android lean mass at roughly 4.1 kg where MRI found 1.7 kg; in women, DXA reported 2.9 kg versus MRI’s 1.1 kg. More concerning for longitudinal studies of HRT, MRI detected a 4-5% decline in muscle and lean mass over time that DXA completely missed, with DXA actually showing lean mass increases in women at follow-up.24PubMed Central. Comparing DXA and MRI body composition measurements in cross-sectional and longitudinal cohorts This means that studies relying solely on DXA to track body composition changes during HRT may be getting a distorted picture, particularly when the question involves simultaneous changes in fat and muscle.
For anyone tracking their own body composition changes during hormone therapy, the practical takeaway is that no single measurement captures the full story. Waist circumference is free and easy but misses what is happening under the surface. DXA gives useful fat distribution data but may mislead on lean mass trends. MRI is the gold standard but is expensive and rarely available for routine monitoring. The most reliable approach is to use a consistent method over time and pay attention to the direction of change rather than fixating on any single number.